docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2023-22-8-51-54docru-242Research ArticleКАРДИОМЕТАБОЛИЧЕСКАЯ МЕДИЦИНАCARDIOMETABOLIC MEDICINEДиабетопороз и риск тромбозовDiabetoporosis and Risk of Thrombosishttps://orcid.org/0000-0002-0940-3469ДоскинаЕ. В.DoskinaE. V.

Доскина Елена Валерьевна - к. м. н., доцент кафедры эндокринологии

125284, г. Москва, 2-й Боткинский проезд, д. 7

72nd Botkinsky pr-d, Moscow, 125284

evd-evd2008@yandex.ruФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской ФедерацииРоссияRussian Medical Academy of Continuous Professional EducationRussian Federation202318022025228КАРДИОМЕТАБОЛИЧЕСКАЯ МЕДИЦИНА5154Copyright © Доскина Е.В., 20252025Доскина Е.В.Doskina E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/242

Цель обзора. Оценка факторов риска тромбозов у пациентов с остеопорозом, индуцированным сахарным диабетом.Основные положения. Остеопороз является распространенным многофакторным заболеванием с высоким риском развития венозных тромбоэмболических осложнений (ВТЭО). Это обусловлено основной патологией — сахарным диабетом, применением лекарственных препаратов для профилактики и лечения остеопороза. Рассмотрены главные патогенетические паттерны развития ВТЭО у пациентов с диабетопорозом. К ним относятся нарушения гемостаза, кальциноз или кальцификация сосудов, лекарственные индукторы, возрастной эстрогенодефицит и др.Заключение. У пациентов с сахарным диабетом, преимущественно 2 типа, на фоне ожирения, более старшего возраста и с остеопорозом повышен риск развития ВТЭО. Целесообразны тщательное обследование больных с факторами риска тромбозов и динамическое наблюдение за ними, индивидуализация и персонификация подходов к лечению остеопороза.

Aim. To assess the risk factors for thrombosis in patients with osteoporosis-induced diabetes mellitus.Key points. Osteoporosis is a common multifactorial disease with a high risk of venous thromboembolic complications (VTEС). This is due to the main pathology — diabetes mellitus, the use of medications for the prevention and treatment of osteoporosis. The main pathogenetic patterns of VTEС development in patients with diabetoporosis are considered. These include hemostasis disorders, the calcification or calcification of blood vessels, drug inducers, age-related estrogen deficiency, etc.Conclusion. Patients with diabetes mellitus, mainly type 2, on the background of obesity, older age and with osteoporosis have an increased risk of developing VTEС. Thorough examination of patients with thrombosis risk factors and dynamic monitoring of them, individualization and personification of approaches to the treatment of osteoporosis are advisable.

остеопороздиабетопорозтромбозытерапияosteoporosisdiabetoporosisthrombosistherapyReferencesKanis J.A., Cooper C., Rizzoli R., Reginster J.Y. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 2019;30(1):3–44. DOI: 10.1007/s00198-018-4704-5Kanis J.A., Cooper C., Rizzoli R., Reginster J.Y. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 2019;30(1):3–44. DOI: 10.1007/s00198-018-4704-5Kanis J.A., Cooper C., Rizzoli R., Reginster J.Y. et al. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif. Tissue Int. 2019;104(3):235–38. DOI: 10.1007/s00223-018-00512-xKanis J.A., Cooper C., Rizzoli R., Reginster J.Y. et al. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif. Tissue Int. 2019;104(3):235–38. DOI: 10.1007/s00223-018-00512-xHarris S.S., Nguyen T.V., Howard G.M., Kelly P.J. et al. Genetic and environmental correlations between bone formation and bone mineral density: a twin study. Bone. 1998;22(2):141–5. DOI: 10.1016/s8756-3282(97)00252-4Harris S.S., Nguyen T.V., Howard G.M., Kelly P.J. et al. Genetic and environmental correlations between bone formation and bone mineral density: a twin study. Bone. 1998;22(2):141–5. DOI: 10.1016/s8756-3282(97)00252-4Keen R.W., Hart D.J., Lanchbury J.S., Spector T.D. Association of early osteoarthritis of the knee with a Taq I polymorphism of the vitamin D receptor gene. Arthritis Rheum. 1997;40(8):1444–9. DOI: 10.1002/art.1780400812Keen R.W., Hart D.J., Lanchbury J.S., Spector T.D. Association of early osteoarthritis of the knee with a Taq I polymorphism of the vitamin D receptor gene. Arthritis Rheum. 1997;40(8):1444–9. DOI: 10.1002/art.1780400812Колбин А.С., Касимова А.Р., Гиляревский С.Р. Фармакоэкономическая оценка применения апиксабана для лечения и профилактики венозных тромбоэмболий в общей популяции и популяции пациентов, страдающих онкологическими заболеваниями. Качественная клиническая практика. 2022;4:38–49.Kolbin A.S., Kasimova A.R., Gilyarevskiy S.R. Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases. Good Clinical Practice. 2022;4:38–49. (in Russian). DOI: 10.37489/2588-0519-2022-4-38-49Sare G.M., Gray L.J., Bath P.M.W. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur. Heart J. 2008;29(16):2031–41. DOI: 10.1093/eurheartj/ehn299Sare G.M., Gray L.J., Bath P.M.W. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur. Heart J. 2008;29(16):2031–41. DOI: 10.1093/eurheartj/ehn299Canonico M., Plu-Bureau G., Lowe G.D., Scarabin P.Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227–31. DOI: 10.1136/bmj.39555.441944.BECanonico M., Plu-Bureau G., Lowe G.D., Scarabin P.Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227–31. DOI: 10.1136/bmj.39555.441944.BEFarquhar C.M., Marjoribanks J., Lethaby A., Lamberts Q. et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 2005;20(3):CD004143. DOI: 10.1002/14651858.CD004143.pub2Farquhar C.M., Marjoribanks J., Lethaby A., Lamberts Q. et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 2005;20(3):CD004143. DOI: 10.1002/14651858.CD004143.pub2Wiegratz I., Kuhl H. Metabolic and clinical effects of progestogens. Eur. J. Contracept. Reprod. Health Care. 2006;11(3):153–61. DOI: 10.1080/13625180600772741Wiegratz I., Kuhl H. Metabolic and clinical effects of progestogens. Eur. J. Contracept. Reprod. Health Care. 2006;11(3):153–61. DOI: 10.1080/13625180600772741Ворожцова И.Н., Будникова О.В., Афанасьев С.А., Кондратьева Д.С. Влияние сахарного диабета 2-го типа на миокард пациентов с ишемической болезнью сердца. Сибирский журнал клинической и экспериментальной медицины. 2018;33(1):14–20.Vorozhtsova I.N., Budnikova O.V., Afanasyev S.A., Kondratieva D.S. Influence of type 2 diabetes on the myocardium of patients with ischemic heart disease. Siberian Journal of Clinical and Experimental Medicine. 2018;33(1): 14–20. (in Russian). DOI: 10.29001/2073-8552-2018-33-1-14-20Токмакова А.Ю., Егорова Д.Н., Доронина Л.П. Поражения нижних конечностей при сахарном диабете. Ожирение и метаболизм. 2017;14(1):41–7.Tokmakova A.Yu., Egorova D.N., Doronina L.P. Foot disorders in diabetes mellitus. Obesity and Metabolism. 2017;14(1):41–7. (in Russian). DOI: 10.14341/OMET2017141-47Cauley J.A., Norton L., Lippman M.E., Eckert S. et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat. 2001;65(2):125–34. DOI: 10.1023/a:1006478317173Cauley J.A., Norton L., Lippman M.E., Eckert S. et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat. 2001;65(2):125–34. DOI: 10.1023/a:1006478317173Zwankenberg S.R., van der Schouw Y.T., Schalkwijk C.G., Spijkerman A.M.W. et al. Bone markers and cardiovascular risk in type 2 diabetes patients. Cardiovasc. Diabetol. 2018;17(1):45. DOI: 10.1186/s12933-018-0691-2Zwankenberg S.R., van der Schouw Y.T., Schalkwijk C.G., Spijkerman A.M.W. et al. Bone markers and cardiovascular risk in type 2 diabetes patients. Cardiovasc. Diabetol. 2018;17(1):45. DOI: 10.1186/s12933-018-0691-2Jeffcoate W.J., Rasmussen L.M., Hofbauer L.C., Game F.L. Medial arterial calcification in diabetes and its relationship to neuropathy. Diabetologia. 2009;52(12):2478–88. DOI: 10.1007/s00125-009-1521-6Jeffcoate W.J., Rasmussen L.M., Hofbauer L.C., Game F.L. Medial arterial calcification in diabetes and its relationship to neuropathy. Diabetologia. 2009;52(12):2478–88. DOI: 10.1007/s00125-009-1521-6Долженко А., Рихтер Т., Сагаловски С. Атеросклероз, кальцификация сосудов и понижение плотности костной ткани (остеопороз): общность патофизиологических механизмов развития заболеваний и поиск новых средств двойной терапии. Атеросклероз. 2016;12(4):44–67.Dolzhenko A., Richter T., Sagalovsky S. Atherosclerosis, vascular calcification and bone loss (osteoporosis): common pathophysiological mechanisms development of the diseases and research novel drags for dual therapy. Ateroscleroz. 2016;12(4):44–67. (in Russian)Harper E.M., Forde H., Davenport C., Rochfort K.D. et al. Vascular calcification in type-2 diabetes and cardiovascular disease: integrative roles for OPG, RANKL and TRAIL. Vascul. Pharmacol. 2016;82:30–40. DOI: 10.1016/j.vph.2016.02.003Harper E.M., Forde H., Davenport C., Rochfort K.D. et al. Vascular calcification in type-2 diabetes and cardiovascular disease: integrative roles for OPG, RANKL and TRAIL. Vascul. Pharmacol. 2016;82:30–40. DOI: 10.1016/j.vph.2016.02.003Moon A.R., Park Y., Chang J.H., Lee S.S. Inverse regulation of serum osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand levels in patients with leg lesional vascular calcification: an observational study. Medicine (Baltimore). 2019;98(10):e14489. DOI: 10.1097/MD.0000000000014489Moon A.R., Park Y., Chang J.H., Lee S.S. Inverse regulation of serum osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand levels in patients with leg lesional vascular calcification: an observational study. Medicine (Baltimore). 2019;98(10):e14489. DOI: 10.1097/MD.0000000000014489Zhou S., Fang X., Xin H., Li W. et al. Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jk/Msx2 signaling pathway. PLoS One. 2013; 8(7):e68987. DOI: 10.1371/journal.pone.0068987Zhou S., Fang X., Xin H., Li W. et al. Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jk/Msx2 signaling pathway. PLoS One. 2013; 8(7):e68987. DOI: 10.1371/journal.pone.0068987Петриков А.С. Антикоагулянтная терапия у пациентов с ожирением. Флебология. 2022;16(2–2):22–3.Petrikov A.S. Anticoagulant therapy in patients with obesity. Flebologiya. 2022;16(2–2):22–3. (in Russian)Dragoman M.V., Tepper N.K., Fu R., Curtis K.M. et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int. J. Gynaecol. Obstet. 2018;141(3):287–94. DOI: 10.1002/ijgo.12455Dragoman M.V., Tepper N.K., Fu R., Curtis K.M. et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int. J. Gynaecol. Obstet. 2018;141(3):287–94. DOI: 10.1002/ijgo.12455Roach R.E., Helmerhorst F.M., Lijfering W.M., Stijnen T. et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst. Rev. 2015;2015(8):CD011054. DOI: 10.1002/14651858.CD011054.pub2Roach R.E., Helmerhorst F.M., Lijfering W.M., Stijnen T. et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst. Rev. 2015;2015(8):CD011054. DOI: 10.1002/14651858.CD011054.pub2Van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J. et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921. DOI: 10.1136/bmj.b2921Van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J. et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921. DOI: 10.1136/bmj.b2921Anderson F.A. Jr, Spencer F.A. Risk factors for venous thromboembolism. Circulation. 2003;107(23 suppl.1):I9–16. DOI: 10.1161/01.CIR.0000078469.07362.E6Anderson F.A. Jr, Spencer F.A. Risk factors for venous thromboembolism. Circulation. 2003;107(23 suppl.1):I9–16. DOI: 10.1161/01.CIR.0000078469.07362.E6Halil M., Cankurtaran M., Yavuz B.B., Ulger Z. et al. Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. Ann. Pharmacother. 2007;41(1):41–5. DOI: 10.1345/aph.1H506Halil M., Cankurtaran M., Yavuz B.B., Ulger Z. et al. Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. Ann. Pharmacother. 2007;41(1):41–5. DOI: 10.1345/aph.1H506Cummings S.R., Eckert S., Krueger K.A., Grady D. еt al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23):2189–97. DOI: 10.1001/jama.281.23.2189Cummings S.R., Eckert S., Krueger K.A., Grady D. еt al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23):2189–97. DOI: 10.1001/jama.281.23.2189Vickers M.R., MacLennan A.H., Lawton B., Ford D. et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335(7613):239. DOI: 10.1136/bmj.39266.425069.ADVickers M.R., MacLennan A.H., Lawton B., Ford D. et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335(7613):239. DOI: 10.1136/bmj.39266.425069.ADBarrett-Connor E., Mosca L., Collins P., Geiger M.J. et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 2006;355(2):125–37. DOI: 10.1056/NEJMoa062462Barrett-Connor E., Mosca L., Collins P., Geiger M.J. et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 2006;355(2):125–37. DOI: 10.1056/NEJMoa062462Vestergaard P., Schwartz K., Pinholt E.M., Rejnmark L. et al. Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism. Osteoporos. Int. 2010;21(9):1591–7. DOI: 10.1007/s00198-009-1091-yVestergaard P., Schwartz K., Pinholt E.M., Rejnmark L. et al. Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism. Osteoporos. Int. 2010;21(9):1591–7. DOI: 10.1007/s00198-009-1091-y

The authors declare that there are no conflicts of interest present.